Austin A. Whitman

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This study shows vandetanib enhances tamoxifen sensitivity in ER+ breast cancer by reprogramming ER gene regulation and kinase networks, identifying adaptive resistance pathways and response signatures.

The paper identifies non-genetic resistance mechanisms in dedifferentiated liposarcoma to abemaciclib by analyzing cell-cycle regulators in cell lines and patient samples.

This paper introduces a multimodal framework to identify drug-responsive subpopulations in triple-negative breast cancer by integrating bulk and single-cell transcriptomics data.